GOOSE portfolio company Saranas heads to clinical trials
Saranas Inc, a GOOSE portfolio company and Houston-based medical device startup, recently closed a round of $2.8 million to kick off clinical trails for their Early Bird Bleed Monitoring System. This round brings their total funding to $12 million.
Early Bird Bleed Monitoring System, invented by Dr. Mehdi Razavi at the Texas Heart Institute, is meant to detect bleeding complications during procedures. The company anticipates FDA approval in early 2019.
In 2017, Saranas was named a finalist for the International Cardiovascular Innovation Award: one of the most prestigious awards for medical startups worldwide.
Larry Lawson, GOOSE board member, and Kevin Maples, a close friend of GOOSE and son-in-law of GOOSE member Dan Steppe, sit on the Board of Directors for Saranas.
A big thank you to Houston Innovation Map and Business Wire for covering Saranas in full detail and the Texas Medical Center Innovation Institute for the support offered to Saranas and countless other healthcare startups.
Goose Capital, Inc. is an investment firm comprised of former Fortune 500 executives, industry leaders, and serial entrepreneurs. Membership in Goose Capital is limited to executives who have founded or run major enterprises and who are willing to invest in and mentor early stage companies. Goose Capital primarily invests in early-stage companies with proprietary and disruptive technology, manageable capital needs, large addressable markets, the prospect for high margins and an exit strategy within a five-year time period. It typically invests in convertible debt and Series A preferred stock, although it reserves capital for follow-on investments in its portfolio companies.